ライフサイエンスコーパス: envelope glycoprotein

1 epitope in the gp120 C1 region of the HIV-1 envelope glycoprotein.

2 HSV) entry through interactions with a viral envelope glycoprotein.

3 vity of SERINC5 with remodeling of the HIV-1 envelope glycoprotein.

4 immunosuppression mediated by the retroviral envelope glycoprotein.

5 lizing Abs specific for the V2 region of the envelope glycoprotein.

6 m by which HCV masks such epitopes on its E2 envelope glycoprotein.

7 more easily produced soluble version of the envelope glycoprotein.

8 xosome mimicry mechanism does not require an envelope glycoprotein.

9 antigenic site within domain II of the viral envelope glycoprotein.

10 nt the membrane-proximal region of the HIV-1 envelope glycoprotein.

11 lizing antibodies by HIV-1 vaccines based on envelope glycoproteins.

12 through active participation of Sendai viral envelope glycoproteins.

13 fford immunosuppressive activity to distinct envelope glycoproteins.

14 -retroviral vectors pseudotyped with various envelope glycoproteins.

15 emerging viruses for the processing of their envelope glycoproteins.

16 in multiple respects from the natural HIV-1 envelope glycoproteins.

17 (MACV) and Junin virus (JUNV), bound to the envelope glycoprotein 1 (GP1) with JUNV monoclonal antib

18 e show that transgenic mice expressing HIV-1 envelope glycoprotein 120 in their central nervous syste

19 he high-mannose glycans found on the surface envelope glycoprotein-120 (gp120).

20 Numerous studies of the anti-HIV-1 envelope glycoprotein 41 (gp41) broadly neutralizing ant

21 f the interaction between the gp120 exterior envelope glycoprotein and CD4; (ii) premature triggering

22 s target novel conserved epitopes within the envelope glycoprotein and exhibit protective efficacy in

23 D), in the transmembrane (TM) subunit of the envelope glycoprotein and identified two naturally polym

24 ction bind to conserved regions on the virus envelope glycoprotein and potently neutralize the majori

25 mutations stabilize the ground state of the envelope glycoprotein and should thus be useful in the d

26 s, a key one being that between the viral E2 envelope glycoprotein and the CD81 receptor.

27 eir host cells via interaction between their envelope glycoproteins and cell-surface glycosaminoglyca

28 the dynamic and complex nature of this viral envelope glycoprotein, and can serve as a reference for

29 enipavirus The attachment (G) and fusion (F) envelope glycoproteins are both required for viral entry

30 ing antibody (bNAb) responses targeting E1E2 envelope glycoproteins are generated in many individuals

31 Viral envelope glycoproteins are important for viral pathogeni

32 y suggesting that at the virion surface, HCV envelope glycoproteins are not accessible for HS binding

33 HIV-1 envelope glycoproteins are targets of neutralizing antib

34 rmined by the co-receptor usage of the viral envelope glycoproteins as well as IFITM subcellular loca

35 ection, the production of antibodies against envelope glycoprotein B (gB) is delayed, compared with p

36 ction against HCMV infection, and the virion envelope glycoprotein B (gB) serves as a major target of

37 Ebola, influenza and numerous other viruses, envelope glycoproteins bind the infecting virion to cell

38 f human cells is the processing of the viral envelope glycoprotein by the cellular subtilisin kexin i

39 airs the normal cellular trafficking of JSRV envelope glycoproteins by sequestering them within the G

40 The fusion peptide of the envelope glycoprotein can be targeted by anchor inhibito

41 of concept that rational engineering of HCV envelope glycoproteins can be used to modulate E2 antige

42 that a single missense mutation in the viral envelope glycoprotein complex (GPC) is responsible for a

43 427 in the fusion subunit (GP2) of the viral envelope glycoprotein complex (GPC), thereby raising con

44 protein O, a receptor binding subunit for an envelope glycoprotein complex involved in entry.

45 cell-specific receptors by one of the viral envelope glycoprotein complexes.

46 forms of CD4, CD4bs antibodies poorly induce envelope glycoprotein conformations that efficiently bin

47 deficiency virus (HIV and SIV, respectively) envelope glycoproteins contain a highly conserved, membr

48 Although isolated HCV envelope glycoproteins could interact with heparin, none

49 Out of the eight HSV-2 proteins, the envelope glycoprotein D (gD), the tegument protein VP22

50 bodies fused to a receptor-binding-deficient envelope glycoprotein D (gD).

51 ing of the CD4-mimetic compound to the HIV-1 envelope glycoproteins depends upon how many of the thre

52 esent evidence that these stabilized soluble envelope glycoproteins differ in multiple respects from

53 fic mutations in the CT of a gammaretroviral envelope glycoprotein distinctly affect infectivity of t

54 neutralizing antibodies in complex with the envelope glycoprotein E from dengue virus serotype 2, re

55 Abs that recognize the envelope glycoproteins E1 and E2 are generated during th

56 The HCV envelope glycoproteins E1 and E2 mediate viral entry, wi

57 sed on the partial crystal structures of the envelope glycoproteins E1 and E2.

58 The viral "spike" of HCV is formed by two envelope glycoproteins, E1 and E2, which together mediat

59 eviously, we demonstrated that a recombinant envelope glycoprotein (E1E2) vaccine (genotype 1a) elici

60 analyzed the interaction of apoE with viral envelope glycoprotein E2 and HCV virions by immunoprecip

61 odies showed that conformational epitopes of envelope glycoprotein E2 domains B and C were exposed af

62 s (NAbs) through molecular features of viral envelope glycoprotein E2, including hypervariable region

63 ed on structures of antibodies targeting HCV envelope glycoprotein E2, we designed immunogens to modu

64 ion with ChAdOx1-GnGc vaccine, encoding RVFV envelope glycoproteins, elicits high-titre RVFV-neutrali

65 , Ebola, Lassa or vesicular stomatitis virus envelope glycoproteins enabled us to study entry of viru

66 Membrane fusion induced by the envelope glycoprotein enables the intracellular replicat

67 ctural polyprotein Gag and the clustering of envelope glycoprotein Env for infectivity.

68 turation process involving the clustering of envelope glycoprotein Env.

69 The HIV-1 envelope glycoprotein (Env) (gp120-gp41)(3) is the targe

70 s starts with interactions between the viral envelope glycoprotein (Env) and cellular CD4 receptors a

71 1 enters cells through binding between viral envelope glycoprotein (Env) and cellular receptors to in

72 binds avidly and cooperatively to the HIV-1 envelope glycoprotein (Env) and is more potent than the

73 Using the HIV-1 envelope glycoprotein (Env) and its interaction with rec

74 HIV-1 entry into cells is mediated by the envelope glycoprotein (Env) and represents an attractive

75 and guide them to cells expressing the HIV-1 envelope glycoprotein (Env) are a promising new weapon f

76 ane-proximal external region (MPER) of HIV-1 envelope glycoprotein (Env) can be targeted by neutraliz

77 Advances in HIV-1 envelope glycoprotein (Env) design generate native-like

78 HIV envelope glycoprotein (Env) exhibits extreme antigenic v

79 HIV-1 envelope glycoprotein (Env) glycosylation is important b

80 The envelope glycoprotein (Env) gp120/gp41 is required for H

81 of the human immunodeficiency virus (HIV)-1 envelope glycoprotein (Env) gp41 subunit plays a critica

82 izing antibodies (bNAbs) targeting the HIV-1 envelope glycoprotein (Env) have been shown to protect n

83 Soluble forms of trimeric HIV-1 envelope glycoprotein (Env) have long been sought as imm

84 izing antibodies (bNAbs) targeting the HIV-1 envelope glycoprotein (Env) have promising utility in pr

85 Designing an effective HIV-1 envelope glycoprotein (Env) immunogen for elicitation of

86 ive studies with subtype A BG505-derived HIV envelope glycoprotein (Env) immunogens have revealed tha

87 One efficient mechanism is to keep its envelope glycoprotein (Env) in its "closed" conformation

88 embly and mediating the incorporation of the envelope glycoprotein (Env) into assembling particles.

89 The HIV-1 envelope glycoprotein (Env) is a trimer of gp120/gp41 he

90 The HIV envelope glycoprotein (Env) is covered in an array of ho

91 The trimeric HIV-1 envelope glycoprotein (Env) is critical for host immune

92 The fusion peptide (FP) of HIV-1 envelope glycoprotein (Env) is essential for mediating v

93 The HIV envelope glycoprotein (Env) is extensively modified with

94 The gp120/gp41 HIV-1 envelope glycoprotein (Env) is highly glycosylated, with

95 ditionally, the mechanism by which the HIV-1 envelope glycoprotein (Env) is recruited to the VS remai

96 The HIV-1 envelope glycoprotein (Env) is sparsely incorporated ont

97 ycans surrounding the N332 glycan on the HIV envelope glycoprotein (Env) is targeted by multiple broa

98 The envelope glycoprotein (Env) is the major target for HIV-

99 HIV-1 envelope glycoprotein (Env) is the sole target for broad

100 Since the envelope glycoprotein (Env) is the target of neutralizin

101 , viral escape through mutation of the HIV-1 envelope glycoprotein (Env) limits clinical applications

102 esidues (G382R and H442Y) into the SIVmac239 envelope glycoprotein (Env) markedly increased its neutr

103 The development of soluble envelope glycoprotein (Env) mimetics displaying ordered

104 Binding of the gp120 surface subunit of the envelope glycoprotein (Env) of HIV-1 to CD4 and chemokin

105 nformation of HIV-1 Env.IMPORTANCE The HIV-1 envelope glycoprotein (Env) opens in response to recepto

106 Structure determination of the HIV-1 envelope glycoprotein (Env) presented a number of challe

107 ies (MAbs) to distinct epitopes on the viral envelope glycoprotein (Env) provides the potential to us

108 r to other type I fusion machines, the HIV-1 envelope glycoprotein (Env) requires proteolytic activat

109 We describe a new recombinant native-like envelope glycoprotein (Env) SOSIP trimer, termed AMC009,

110 entation to the immune system.IMPORTANCE The envelope glycoprotein (Env) spike on the surface of huma

111 tralizing antibodies (bNAbs) that target the envelope glycoprotein (Env) spike on the virus.

112 broadly neutralizing antibodies to the HIV-1 envelope glycoprotein (Env) spike.

113 The trimeric envelope glycoprotein (Env) spikes on HIV-1 are known to

114 t efforts to optimize its utility.IMPORTANCE Envelope glycoprotein (Env) spikes on the surface of hum

115 are among viruses for having a low number of envelope glycoprotein (Env) spikes per virion, i.e., app

116 re of these proteins is their mimicry of the envelope glycoprotein (Env) structure on virus particles

117 alizing antibodies (bNAbs) against the HIV-1 envelope glycoprotein (Env) suppress viremia in animal m

118 HIV-1 encodes an envelope glycoprotein (Env) that contains a long cytopla

119 this insight to generate a form of SIVmac239 envelope glycoprotein (Env) that utilized rhesus CD4 mor

120 inner domain of gp120 are required for HIV-1 envelope glycoprotein (Env) transitions to the CD4-bound

121 s type 1 (HIV-1) entry into cells, the viral envelope glycoprotein (Env) trimer [(gp120/gp41)(3)] bin

122 The HIV-1 envelope glycoprotein (Env) trimer [(gp120/gp41)(3)] is

123 alizing antibodies (bNAbs) against the HIV-1 envelope glycoprotein (Env) trimer has facilitated its s

124 human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein (Env) trimer maintain the metastab

125 The HIV-1 envelope glycoprotein (Env) trimer mediates cell entry a

126 The HIV-1 envelope glycoprotein (Env) trimer mediates virus entry

127 human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein (Env) trimer of gp120-gp41 heterod

128 The envelope glycoprotein (Env) trimer on the surface of HIV

129 alizing antibodies (bNAbs) against the HIV-1 envelope glycoprotein (Env) trimer remains a major vacci

130 riggers serial conformational changes in the envelope glycoprotein (Env) trimer that result in the fu

131 human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein (Env) trimer, (gp120/gp41)(3) Solu

132 The HIV-1 envelope glycoprotein (Env) trimer, composed of gp120 an

133 1) entry into cells is mediated by the viral envelope glycoprotein (Env) trimer, which consists of th

134 expanded the targetable surface on the HIV-1 envelope glycoprotein (Env) trimer.

135 Soluble envelope glycoprotein (Env) trimers (SOSIP.664 gp140) ar

136 Well-ordered HIV-1 envelope glycoprotein (Env) trimers are prioritized for

137 he immunogenicity of native-like recombinant envelope glycoprotein (Env) trimers based on viral seque

138 Soluble recombinant native-like (NL) envelope glycoprotein (Env) trimers of various human imm

139 Soluble, recombinant native-like envelope glycoprotein (Env) trimers of various human imm

140 The homotrimeric HIV-1 envelope glycoprotein (Env) undergoes receptor-triggered

141 Current HIV-1 envelope glycoprotein (Env) vaccine candidates elicit pr

142 antibodies against vulnerable regions on the envelope glycoprotein (Env) viral spike.

143 Interaction of the viral envelope glycoprotein (Env) with a specific cellular rec

144 nserved coreceptor-binding site of the HIV-1 envelope glycoprotein (Env), can increase the associatio

145 t epitope at the gp120-gp41 interface of the envelope glycoprotein (Env), involving the glycan N88 an

146 dense array of N-linked glycans on the HIV-1 envelope glycoprotein (Env), known as the "glycan shield

147 immunogens that antigenically mimic the HIV envelope glycoprotein (Env), such as the soluble cleaved

148 HIV-1 envelope glycoprotein (Env), which consists of trimeric

149 antitatively or qualitatively modulate HIV-1 envelope glycoprotein (Env)-specific B and T cell respon

150 ross-reactive antibodies that mediated HIV-1 envelope glycoprotein (Env)-targeted ADCC were frequentl

151 Abs) target five major epitopes on the HIV-1 envelope glycoprotein (Env).

152 y include a recombinant version of the viral envelope glycoprotein (Env).

153 rstanding germline bNAb recognition of HIV-1 envelope glycoprotein (Env).

154 nizing epitopes in the V1/V2 region of HIV-1 envelope glycoprotein (Env).

155 essing and virion incorporation of the viral envelope glycoprotein (Env).

156 to the CD4 binding site (CD4bs) on the HIV-1 envelope glycoprotein (Env).

157 ng antibodies (bnAbs) that bind to the viral envelope glycoprotein (Env).

158 ) targeting five major epitopes on the HIV-1 envelope glycoprotein (Env).

159 target CD4-induced (CD4i) epitopes on HIV-1 envelope glycoprotein (Env).

160 human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein (Env).

161 , HIV-1 limits the surface expression of its envelope glycoprotein (Env).

162 V3, V4, and CD4-binding regions of the HIV-1 envelope glycoprotein (Env).

163 ion of replication-competent provirus, HIV-1 envelope glycoproteins (Env) are expressed and accumulat

164 HIV-1-infected cells presenting envelope glycoproteins (Env) in the CD4-bound conformati

165 cytotoxicity (ADCC) requires the presence of envelope glycoproteins (Env) in the CD4-bound conformati

166 The human immunodeficiency virus (HIV-1) envelope glycoproteins (Env) mediate virus entry through

167 eral strategies to limit the exposure of its envelope glycoproteins (Env) on the surface of infected

168 HIV-1 conceals epitopes of its envelope glycoproteins (Env) recognized by antibody (Ab)

169 Stabilized HIV-1 envelope glycoproteins (Env) that resemble the native En

170 1) entry into cells is mediated by the viral envelope glycoproteins (Env), a trimer of three gp120 ex

171 HIV-1 and its surface envelope glycoproteins (Env), gp120 and gp41, have evolv

172 onses to the conserved elements of the HIV-1 envelope glycoproteins (Env), including the primary rece

173 ause of the genetic variability of the HIV-1 envelope glycoproteins (Env), the elicitation of neutral

174 1 into target cells is mediated by the viral envelope glycoproteins (Env).

175 HIV-1 envelope glycoprotein [Env; trimeric (gp160)(3) cleaved

176 Our phase I study with recombinant HCV E1/E2 envelope glycoprotein (EnvGPs) as a candidate vaccine di

177 Vaccine-elicited antibodies target the viral envelope glycoproteins (Envs) and can potentially inhibi

178 The envelope glycoproteins (Envs) from human immunodeficienc

179 The envelope glycoproteins (Envs) of HIV-1 are embedded in t

180 The envelope glycoproteins (Envs) of HIV-1 continuously evol

181 and microbicides that target glycans on the envelope glycoproteins (Envs) of HIV-1.

182 The envelope glycoproteins (Envs) on the surfaces of HIV-1 p

183 In presence of cells expressing HIV-1 envelope glycoproteins (Envs), these BiKEs activated spe

184 ata suggest that HSV-1 gC protects the viral envelope glycoproteins essential for entry, including gB

185 ate receptors as targets for fusion with HIV envelope glycoprotein-expressing pseudovirus particles w

186 derived HCV containing patient-derived viral envelope glycoproteins from 22 HCV variants isolated fro

187 HCV (HCVcc) containing patient-derived viral envelope glycoproteins from 22 HCV variants isolated fro

188 (M) segment of the viral genome encodes two envelope glycoproteins, G(N) and G(C), which together fo

189 erpes simplex virus (HSV), requires the four envelope glycoproteins gB, gD, gH, and gL.

190 e, we describe the crystal structure of HTNV envelope glycoprotein Gn, an integral component of the G

191 The envelope glycoproteins Gn and Gc form heterodimers that

192 The hantavirus envelope glycoproteins Gn and Gc mediate virion assembly

193 Fusion is mediated by the EBOV envelope glycoprotein GP, which consists of subunits GP1

194 ane proximal external region (MPER) of HIV-1 envelope glycoprotein (gp) 41 is an attractive vaccine t

195 The Ebola virus (EBOV) envelope glycoprotein (GP) is a membrane fusion machine

196 ovalent vaccines, which all utilize the sole envelope glycoprotein (GP), do not protect against heter

197 at the Ebola virus matrix protein, VP40, and envelope glycoprotein, GP, each cooperate with BST2 to i

198 Although the Ebola virus envelope glycoprotein (GP1,2) antagonizes the trapping o

199 d a neuropathic pain model of perineural HIV envelope glycoprotein gp120 application onto the rat sci

200 The HIV-1 envelope glycoprotein gp120 is heavily glycosylated and

201 ns via targeting the CD4 binding site of the envelope glycoprotein gp120.

202 The HIV envelope glycoprotein (gp120) is neurotoxic and has been

203 We tested this phenomenon in the HIV envelope glycoprotein (gp120), and the V-gene that encod

204 rst time demonstrates a role of POX in HIV-1 envelope glycoprotein (gp120)-induced neuronal autophagy

205 Like all other secretory proteins, the HIV-1 envelope glycoprotein gp160 is targeted to the endoplasm

206 on F427I in the transmembrane region of JUNV envelope glycoprotein GP2 has been shown to attenuate th

207 bstitutions in the cytoplasmic tail of viral envelope glycoprotein gp41 of the neurovirulent virus SI

208 cted for viruses with mutations in the viral envelope glycoprotein, gp41.

209 moderately reduced trafficking of the viral envelope glycoprotein GP64 to the plasma membrane but dr

210 rus, which binds to the cell surface via the envelope glycoprotein Gp64.

211 Overproduction of non-ecotropic ERV (NEERV) envelope glycoprotein gp70 and resultant nephritis occur

212 into the host cell is promoted by the virus envelope glycoprotein GPC.

213 l membranes, a process mediated by the virus envelope glycoprotein GPC.

214 lecule inhibitors that target the arenavirus envelope glycoprotein (GPC) have recently been identifie

215 dentified and shown to act on the arenavirus envelope glycoprotein (GPC) to prevent membrane fusion.

216 Unlike other viral envelope glycoproteins, GPC contains a myristoylated sta

217 The major bat influenza A virus envelope glycoprotein, haemagglutinin, does not bind the

218 his importance of structural dynamics of HCV envelope glycoproteins has critical implications for vac

219 human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein have been studied extensively for

220 We found that the HIV-1 membrane envelope glycoproteins have a unique pattern of carbohyd

221 The envelope glycoproteins have an extensive coat of carbohy

222 virus (VSV) encoding the hemagglutinin-like envelope glycoproteins HL17 or HL18 in place of the VSV

223 The envelope glycoprotein I (gI) of herpes simplex virus 1 (

224 dly neutralizing antibodies (bNAbs) by HIV-1 envelope glycoprotein immunogens would be a major advanc

225 cryo-EM) and allowed us to stabilize the HIV envelope glycoprotein in a functional state.

226 in providing the necessary stability to the envelope glycoprotein in order to withstand the interact

227 Despite the known function of viral envelope glycoproteins in catalyzing fusion with cellula

228 , and call for a reassessment of the role of envelope glycoproteins in infection.

229 res the coordinated action of multiple virus envelope glycoproteins, including gH, gL, and gB.

230 Our findings show that envelope-glycoprotein-independent fusion mechanisms are

231 Here, we report that B virus lacking the gD envelope glycoprotein infects both human and monkey cell

232 The hepatitis C virus (HCV) E2 envelope glycoprotein is crucial for virus entry into he

233 The E2 envelope glycoprotein is the primary target of human neu

234 zation through structure-based design of the envelope glycoproteins is a promising route to an effect

235 E The "open" CD4-bound conformation of HIV-1 envelope glycoproteins is the primary target of antibody

236 his study, mutations naturally found in some envelope glycoproteins lacking immunosuppressive activit

237 triggering of conformational changes in the envelope glycoproteins, leading to irreversible inactiva

238 read, deep-sequenced data of full-length HCV envelope glycoprotein, longitudinally sampled from acute

239 inhibits HCV infection despite increased HCV envelope glycoprotein-mediated infection of liver cells.

240 The HIV envelope glycoprotein mediates virus entry into target c

241 Efficient engagement with the envelope glycoprotein membrane-proximal external region

242 additionally express the HBV middle surface envelope glycoprotein (MHBs) induces functional CD8 T ce

243 E Approximately 50% of the mass of the gp120 envelope glycoprotein of both HIV and SIV is N-linked ca

244 E2, the major envelope glycoprotein of classical swine fever virus (CS

245 The envelope glycoprotein of diverse endogenous and exogenou

246 We then identified the envelope glycoprotein of EIAV as a determinant that also

247 antibody (HC84.26.5D) that recognizes the E2 envelope glycoprotein of hepatitis C virus (HCV).

248 ate the binding affinities between the gp120 envelope glycoprotein of HIV-1 and three broadly neutral

249 pped to a conserved domain of the retroviral envelope glycoprotein of several exogenous as well as en

250 hese two key residues (E14R and A20F) in the envelope glycoprotein of the Friend murine leukemia viru

251 assay to detect antibodies reactive with the envelope glycoprotein of viruses in the genus Henipaviru

252 RNA (mRNA-LNP) encoding the pre-membrane and envelope glycoproteins of a strain from the ZIKV outbrea

253 The trimeric envelope glycoproteins of human immunodeficiency virus t

254 d elicit antibodies that bind to the surface envelope glycoproteins on the membrane of the virus.

255 in perinuclear vesicle-like structures near envelope glycoproteins or mitochondria.

256 MeV envelope glycoproteins preassemble intracellularly into

257 es, our results can guide the improvement of envelope glycoprotein preparations to achieve greater si

258 fferences in the amount of virion-associated envelope glycoprotein, recipient isolates were on averag

259 As gB is an envelope glycoprotein required for fusion with host cell

260 h a conserved linear epitope from the HCV E2 envelope glycoprotein (residues 412 to 423; epitope I),

261 HIV-1 vaccine research, native-like, soluble envelope glycoprotein SOSIP trimers are widely used for

262 The trimeric HIV-1 envelope glycoprotein spike (Env) mediates viral entry i

263 The trimeric envelope glycoprotein spike (Env) of HIV-1 is the target

264 isolated B cells specific for the SARS-CoV-2 envelope glycoprotein spike (S) from a COVID-19-infected

265 tigenic mammalian oligomannoses on the HIV-1 envelope glycoprotein spike that are targets for broadly

266 s to achieve greater similarity to the viral envelope glycoprotein spike, potentially increasing thei

267 the native HIV-1 Env trimer.IMPORTANCE HIV-1 envelope glycoprotein spikes mediate the entry of the vi

268 es.IMPORTANCE Engineered SOSIP trimers mimic envelope-glycoprotein spikes, which stud the surface of

269 Knowledge of the envelope glycoprotein structure and the conformational c

270 re of these proteins is their mimicry of the envelope glycoprotein structure on virus particles that

271 The surface envelope glycoprotein (SU) of Human immunodeficiency vir

272 l region and the transmembrane domain of the envelope glycoprotein subunit gp41, which display differ

273 hat the product of the UL116 gene is an HCMV envelope glycoprotein that forms a novel gH-based comple

274 lizing monoclonal antibodies against the SIV envelope glycoprotein that only block alpha(4)beta(7) bi

275 identify residues in the HIV-1 transmembrane envelope glycoprotein that stabilize the unliganded stat

276 Soluble forms of the envelope glycoproteins that are stable and easily produc

277 er preparations of HCV particles with tagged envelope glycoproteins that enabled ultrastructural anal

278 n(154) glycosylation site in each of the 180 envelope glycoproteins that make up the icosahedral shel

279 al entry into host cells relies on two viral envelope glycoproteins: the attachment (G) and fusion (F

280 ajority of paramyxoviruses utilize two viral envelope glycoproteins: the attachment glycoprotein (G,

281 immunodeficiency virus (SIV) gp120 exterior envelope glycoprotein to CD4 triggers conformational cha

282 sed design of several epitopes of the HCV E2 envelope glycoprotein to engineer its antigenic properti

283 mportance of antibodies targeting the HCV E2 envelope glycoprotein to facilitate viral clearance.

284 However, the relative ability of SIV envelope glycoproteins to bind or utilize these CD4 orth

285 rus (HIV) vaccines is the inability of viral envelope glycoproteins to elicit broad and potent neutra

286 mer are bound and upon the propensity of the envelope glycoproteins to undergo conformational changes

287 hors Gag to the plasma membrane and recruits envelope glycoproteins to virus assembly sites.

288 The envelope glycoprotein trimer (Env) on the surface of HIV

289 ers changes in the conformation of the HIV-1 envelope glycoprotein trimer important for virus entry.

290 We show that a soluble recombinant HIV-1 envelope glycoprotein trimer that adopts a native confor

291 l membranes, a process mediated by the HIV-1 envelope glycoprotein trimer.

292 mponents: 1) IgG Abs reacting with the viral envelope glycoprotein trimeric gp41; 2) produced by plas

293 use of various designs of recombinant HIV-1 envelope glycoprotein trimers that mimic the structure o

294 n of the MV hemagglutinin (H) and fusion (F) envelope glycoproteins; upon receptor engagement by H, t

295 vesicular stomatitis virus-Zaire Ebola virus envelope glycoprotein vaccine (rVSVDeltaG-ZEBOV-GP).

296 vesicular stomatitis virus-Zaire Ebola virus envelope glycoprotein vaccine (rVSVDeltaG-ZEBOV-GP).

297 vesicular stomatitis virus-Zaire Ebola virus envelope glycoprotein vaccine (rVSVG-ZEBOV-GP) across a

298 yment of the rVSVDeltaG-ZEBOV-GP Ebola virus envelope glycoprotein vaccine, available therapeutics, a

299 ibodies recognizing different regions of HCV envelope glycoproteins were also used in a pulldown assa

300 enic NDV strain, in which the ectodomains of envelope glycoproteins were replaced with the correspond